Mephenaqualone

Mephenaqualone emerges from the same chemical lineage as its more famous cousin methaqualone, and it carries a family resemblance that reveals itself within thirty to sixty minutes of ingestion. The onset brings a spreading warmth through the body, beginning in the core and radiating outward to the extremities, as though a gentle internal flame had been lit. The muscles begin to relax in a way that feels more profound than simple sedation -- there is a looseness, a pliability, as though the body has been given permission to stop holding its shape so rigidly.

As the come-up progresses, a distinctive euphoria begins to make itself felt. It is a warm, physical euphoria, rooted more in the body than the mind -- a sensation of being enveloped in comfort, of every surface and position being exactly right. There is a mild disinhibition that softens social boundaries and makes conversation flow more easily, though the sedation that accompanies it can make articulation increasingly effortful. The world takes on a dreamy quality, edges softening and colors seeming slightly richer, as though reality has been viewed through a filter that removes harshness while enhancing warmth.

At the peak, the muscle relaxation and euphoria combine into an experience that is distinctly sensual. Physical touch feels amplified, textures become more interesting, and the body seems to pulse with a quiet pleasure that does not require stimulation to maintain. There is a heaviness to the limbs that makes movement feel like an indulgence rather than a necessity, and the mind drifts in a pleasant, unstructured way, thoughts forming and dissolving without urgency. Coordination is noticeably impaired, and there is a characteristic looseness to movement that reflects the depth of the muscular relaxation. Time perception slows, each moment seeming to contain more sensation than it usually does.

The comedown is a gentle slide into deeper sedation. The euphoria fades gradually, leaving behind the warmth and relaxation, and the pull toward sleep becomes increasingly insistent. Sleep arrives easily and is often described as exceptionally deep and satisfying. Morning brings a mild residual relaxation and a slightly foggy clarity that clears within a few hours.

Mechanism of Action

Mephenaqualone acts as a positive allosteric modulator of GABA-A receptors. Like methaqualone, its precise binding site and receptor subtype selectivity differ from classical benzodiazepines — it interacts with the GABA-A receptor at a distinct site and may show different selectivity across receptor subtypes. This mechanistic distinction from benzodiazepines may partially account for the qualitatively distinct experience described by users of the methaqualone/mephenaqualone class.

Quinazolinone Class Mechanism

2015 research on methaqualone demonstrated that quinazolinones exhibit distinct functional properties at GABA receptor sites compared to both barbiturates and benzodiazepines — they mediate their effects through a different mechanism despite overlapping pharmacological profiles. The specific molecular interactions of mephenaqualone at the GABA-A complex have not been fully characterized, but the compound produces broadly similar functional effects to methaqualone.

Dopaminergic Activity

Like many GABAergic drugs, quinazolinones may produce indirect dopaminergic effects through disinhibition mechanisms in the mesolimbic pathway, contributing to the euphoric component of their subjective profile.

Pharmacokinetics

Pharmacokinetic data specifically for mephenaqualone are not well-characterized in accessible literature. By analogy with methaqualone, oral bioavailability is expected to be high, with onset in 30–60 minutes and duration of 4–8 hours. The route of administration in the Mandrax smoking pattern significantly alters pharmacokinetics — pyrolytic products may have different activity profiles from the parent compound.

Development and Limited Pharmaceutical Use

Mephenaqualone was developed in the mid-20th century as a quinazolinone sedative, sharing the basic pharmacological class with methaqualone. Unlike methaqualone, which achieved widespread pharmaceutical use in multiple countries, mephenaqualone found more limited application and was produced and marketed by fewer pharmaceutical companies.

African Mandrax Culture

The term "Mandrax" in South Africa and other sub-Saharan African countries refers to tablets containing mephenaqualone (sometimes mixed with methaqualone or diphenhydramine) rather than the original Mandrax brand (which contained methaqualone). Mandrax smoking — combining the tablet with cannabis and smoking through a broken bottle neck or modified pipe — developed as a distinct drug use pattern in South Africa beginning in the 1970s–80s and remains prevalent. The social and health impacts of Mandrax use in South Africa represent a significant public health concern distinct from the Western pattern of methaqualone use.

Regulatory Status

Mephenaqualone is a controlled substance in most jurisdictions, typically scheduled alongside methaqualone. Its presence on illicit markets is primarily through illicit manufacture rather than diversion of pharmaceutical product.